EP0892863A1 - Composite fibres, wound dressings incorporating such fibres and a method for making same - Google Patents

Composite fibres, wound dressings incorporating such fibres and a method for making same

Info

Publication number
EP0892863A1
EP0892863A1 EP19970918136 EP97918136A EP0892863A1 EP 0892863 A1 EP0892863 A1 EP 0892863A1 EP 19970918136 EP19970918136 EP 19970918136 EP 97918136 A EP97918136 A EP 97918136A EP 0892863 A1 EP0892863 A1 EP 0892863A1
Authority
EP
European Patent Office
Prior art keywords
fibres
absorbent
weight
composite
alginate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19970918136
Other languages
German (de)
French (fr)
Other versions
EP0892863B1 (en
Inventor
David Kershaw
Peter M. J. Mahoney
Paul Hanmer
David Pritchard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Convatec Technologies Inc
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607600.5A external-priority patent/GB9607600D0/en
Priority claimed from GBGB9618658.0A external-priority patent/GB9618658D0/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0892863A1 publication Critical patent/EP0892863A1/en
Application granted granted Critical
Publication of EP0892863B1 publication Critical patent/EP0892863B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/01Non-adhesive bandages or dressings
    • A61F13/01008Non-adhesive bandages or dressings characterised by the material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives
    • DTEXTILES; PAPER
    • D01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01FCHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F2/00Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof
    • D01F2/24Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof from cellulose derivatives
    • D01F2/28Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof from cellulose derivatives from organic cellulose esters or ethers, e.g. cellulose acetate
    • DTEXTILES; PAPER
    • D01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01FCHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F9/00Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
    • D01F9/04Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of alginates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/06Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings
    • A61F13/064Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings for feet
    • A61F13/069Decubitus ulcer bandages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/00217Wound bandages not adhering to the wound
    • A61F2013/00229Wound bandages not adhering to the wound with alginate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00089Wound bandages
    • A61F2013/00238Wound bandages characterised by way of knitting or weaving
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00365Plasters use
    • A61F2013/00519Plasters use for treating burn
    • A61F2013/00523Plasters use for treating burn with hydrogel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00655Plasters adhesive
    • A61F2013/00719Plasters adhesive adhesives for use on wounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00727Plasters means for wound humidity control
    • A61F2013/00748Plasters means for wound humidity control with hydrocolloids or superabsorbers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F2013/00361Plasters
    • A61F2013/00902Plasters containing means
    • A61F2013/00927Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors
    • A61F2013/00931Plasters containing means with biological activity, e.g. enzymes for debriding wounds or others, collagen or growth factors chitin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/10Scrim [e.g., open net or mesh, gauze, loose or open weave or knit, etc.]
    • Y10T442/102Woven scrim
    • Y10T442/105Comprising a composite fiber
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/40Knit fabric [i.e., knit strand or strip material]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/40Knit fabric [i.e., knit strand or strip material]
    • Y10T442/425Including strand which is of specific structural definition
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/40Knit fabric [i.e., knit strand or strip material]
    • Y10T442/425Including strand which is of specific structural definition
    • Y10T442/438Strand material formed of individual filaments having different chemical compositions

Definitions

  • the invention relates to composite fibres, particularly absorbent composite fibres for use in wound treatment, wound dressings incorporating such fibres and a method for making same.
  • Absorbent fibres for use in wound treatment are well known in the art. Examples include cellulose fibres, chemically modified cellulose fibres, pectin fibres, alginate fibres, chitosan fibres, hyaluronic acid fibres or other polysaccharide fibres or fibres derived from gums.
  • pectin or carboxymethyl cellulose In the treatment of wounds it is desirable to use fibres made from pectin or carboxymethyl cellulose but the known processes for making such fibres are complex and expensive and the resulting fibres not always viable. For instance it is known to make carboxymethyl cellulose fibres by chemically converting preformed cellulose fibres. It is also known that both pectin fibres and carboxymethyl cellulose fibres are difficult to spin.
  • the invention provides an absorbent, composite fibre comprising a matrix of at least 10% and less than 50% by weight of water insoluble alginate having dispersed therein at least 40% of another polysaccharide. Unless otherwise stated all percentages herein are by weight based on the weight of the fibre.
  • the water insoluble alginate effectively provides, as a matrix, a molecular backbone to the fibre that enables the other polysaccharides to be incorporated and results in a fibre that may be spun and otherwise processed.
  • the use of water insoluble alginate for this purpose enables the fibres to be made without the need for complex and expensive processing and without the need to use preformed cellulose as a starting material.
  • Preferred polysaccharides for addition to the alginate backbone are carboxymethyl cellulose and/or pectin.
  • the fibres of the invention rely on the water insoluble alginate to provide integrity to the fibres it is truly surprising that it is possible to make viable fibres processable into products that comprise a minor proportion of insoluble alginate.
  • One of the advantages of such fibres is that they may comprise a major proportion of polysaccharide other than alginate which generally makes them more absorbent than fibres which have insoluble alginates in a major proportion.
  • the fibres comprise, in addition to insoluble alginate, from 40% to 90% of another polysaccharide, more preferably from 60% to 85% and most preferably from 70% to 80% of another polysaccharide which is most preferably carboxymethyl cellulose or pectin or a mixture thereof.
  • Polysaccharides suitable for use in fibres according the invention include carboxymethyl cellulose, carboxyethyl cellulose, other derivatives of cellulose, cellulose, pectin, hyaluronic acid and chitosan.
  • the insoluble alginate is calcium alginate.
  • the fibres comprise from 10% to less than 50% by weight of the fibre of insoluble alginate, more preferably 10% to 49%, more preferably 15% to 40% and most preferably from 20% to 30% by weight of the fibre of water insoluble alginate.
  • the insoluble alginate is calcium alginate.
  • a particularly preferred embodiment of the absorbent, composite fibres of the invention comprise a matrix of 20% to 30% of calcium alginate based on the weight of the fibre having dispersed therein from 55% to 60% of carboxymethyl cellulose and 15% to 20% of pectin based on the weight of the fibre.
  • the invention provides a method for making a composite, absorbent fibre comprising the following steps: (i) adding sodium alginate and another polysaccharide to water to form a dope,-
  • the process enables composite fibres to be prepared which comprise large quantities of other polysaccharides and in particular, carboxymethyl cellulose, pectin or both.
  • the fibres so produced are capable of being spun or otherwise mechanically processed.
  • the resulting fibres have a high tensile strength compared to alginate, carboxymethyl cellulose or pectin alone.
  • fibre means both relatively short, discrete, randomly oriented material (sometimes known as staple fibre) and yarns made therefrom (sometimes known as staple yarn) and relatively long, structured, continuous filament yarn.
  • the fibres may have a staple length of 5mm to 70 mm, more usually 20mm to 50 mm, favourably 25mm to 40 mm.
  • the fibres prepared according to the above described process may be dried using conventional methods, for example, using acetone or hot air drying.
  • Alginates are produced by a variety of micro-organisms and marine algae which are the normal commercial source.
  • the alginates being natural materials show considerable variety but are characterised in being block copolymers, the individual monosaccharide units being arranged into groups as blocks of mannuronic (M) and guluronic (G) residues.
  • M mannuronic
  • G guluronic
  • each polymer chain can contain a proportion of alternating M and G monosaccharide units.
  • the alginate may be obtained from any convenient source, for example L. Hyperborea or Ascophyllum Nodosum or those described in EP-A-0721355 to Bristol-Myers Squibb Company which are particularly preferred.
  • the absorbent, composite fibres are employed in the manufacture of wound dressings. Accordingly the invention provides a wound dressing comprising an absorbent, composite fibre comprising a matrix of between at least 10% and less than 50% of water insoluble alginate having dispersed therein at least 40% of another polysaccharide.
  • the wound dressings may be in the form of swabs, wound pads, wadding ribbons, sponges, nets and bandages and may be used as a primary or secondary dressing especially in the treatment of leg ulcers.
  • the wound dressings according to the invention may benefit from an improved integrity over that of dressings made from alginate, pectin or carboxymethyl cellulose alone.
  • a wound dressing comprising a mixture of discrete textile fibres and discrete absorbent, composite fibres said absorbent, composite fibres comprising a matrix of at least 10% of water insoluble alginate having dispersed therein at least 40% of another polysaccharide.
  • a dressing may have the advantage that it is non-adherent to wound tissue while being absorbent and relatively inexpensive and the added advantage that it may be retained on the wound for longer than conventional cotton gauze.
  • the absorbent, composite fibres according to the invention incorporated in the wound dressing become moist and slippery or gelatinous upon the uptake of wound exudate. This reduces the tendency for the textile fibres to adhere to the wound.
  • textile fibres absorb liquids by capillary action and are not hygroscopic. This means that their absorbencies as measured by the free swell absobancy test are low such as less than l gram of liquid per gram of fibre.
  • Suitable textile fibres can be natural or synthetic depending on the end use of the dressing and method of manufacture. Suitable textile fibres are for instance described in PCT/GB95/00114.
  • the textile fibre is preferably one that can be fused at relatively low temperatures, for example polypropylene. The entire dressing can be heat fused to give a dressing with sufficient tensile strength that it may be removed intact from the wound even though saturated with exudate. This avoids the need for the painstaking removal from the wound of parts of a dressing that has lost its integrity on exposure to exudate.
  • the textile yarn can be polyester, polypropylene or polyamide or any other suitable support yarn.
  • the textile yarn can be polyester, polypropylene or polyamide or any other suitable support yarn.
  • a particularly suitable knit of this type is a Raschel knit as described in Textile Science by Kathryn Hatch, West Publishing Company 1993. If composite fibres are included in both the pillar and the in-laid yarn then the pillar yarn tends to break and shed fibres. If composite fibres are included only in the in-laid yarn then this tendancy is overcome and quite high machine knitting speeds can be achieved and a dressing of better integrity is produced.
  • the invention provides a wound dressing as claimed in claims 11 to 14 wherein the dressing is in the form of a warp knitted fabric comprising pillar yarn and in-laid yarn, the pillar yarn being substantially free of composite fibres.
  • Various optional ingredients can be included in the final composition of the fibres such as preservatives and small amounts of pharmacologically active ingredients.
  • an antibiotic or antimicrobial agent such ⁇ metronidazole, silver sulphadiazine, neomycin or penicillin and antiseptic agent such as povidone iodine, iodine and antiinflammatory agent such as hydrocortisone or triamcinolone acteonide or a skin protective agent such as a zinc oxide can be included.
  • Fibres according to the invention in the form of a continuous yarn were prepared as follows:
  • 800ml of a 6% w/w dope was made by adding 28g of carboxymethyl cellulose (ex Hercules) , 12g of alginate (ex Kelco) , and 8g of pectin (ex Aldrich Ltd) to 752g of deionised water. The mixture was stirred with a high speed mixer until the ingredients had dissolved and the dope allowed to stand overnight to degas.
  • the degassed dope was then poured into a pressure vessel connected to the dope pumping/filtering system of a spinning rig.
  • the pressure vessel was pressurised to 2 to 3 atmospheres with compressed air and the pump, 60 ⁇ m pore size filter and associated pipe work purged to remove any air bubbles.
  • Propan-2-ol was dripped onto the fibres at a rate sufficient to wet the resulting yarn.
  • the yarn was then passed into two baths, the first contained 4L of propan-2-ol and the second contained 2.5L of propan-2-ol.
  • the propan-2-ol was maintained at a concentration to dry the yarn.
  • the yarn was then passed through a set of pinch rollers that serve to apply tension to yarn.
  • the yarn was then wound onto cones.
  • the dope was supplied to the system at 6ml per minute and a speed differential maintained between the first and second godets resulted in a stretch of 60%.
  • the resulting yarn had a denier of 300 to 400.
  • a knitted wound dressing according to the invention was prepared comprising the yarn of example 1 and a crimped polyester yarn.
  • the dressing was knitted on a crochet knitting machine (Model STP7 ex KOHLER) each needle of which creates a chain of interlocked loops (pillar or clain stitches) . These form the warp threads of the dressing.
  • the warp threads are held together by weft threads.
  • 45 warp threads of stiches were knitted from 150 denier crimped polyester yarn. These were held together by 44 threads of the yarn of example 1 (in-laid yarn) to form a dressing.
  • a non-woven wound dressing according to the invention was made by mixing 200g of the aborbent, composite fibres of example 1 cut into 5cm lengths and 200g of polypropylene staple fibre cut to 5cm lengths in a rag roller to randomise the fibre. The mixture of fibres was then carded and cross-lapped into a web of lOOgsm basis weight. The web was then passed through heated callender rollers at 65°C and pressure. The resultant product was slit into discrete dressings 10cm by 10cm square.
  • a staple yarn was made from the composite fibres of the invention in the following way.
  • a mixture of the composite fibre (20kg) and polypropylene (20kg) (all 3 denier) was cut to a staple length of 40mm and converted into a lap of approximately lOOgsm on a conventional short staple scutching line - a Truteschler Opening line.
  • the line comprised a feed table, coarse fibre opener, volumetric feeder, fine opener and lap former.
  • the lap once formed was fed into a worsted type carding machine - a Thibeau CA6 comprising a weigh pan hopper, fibre opening section and a main carding cylinder.
  • the web of fibres formed was condensed into the form of a sliver with an average weight of 5 grammes per metre length.
  • the slivers were then attenuated on a conventional short- staple draw frame - a Platts Globe Draw Frame - in which rollers operated at differential surface speeds to attenuate the multiple feed of slivers (6-8) into a uniform single sliver of uniform weight and thickness (approximately 3g per metre length) .
  • the drawn sliver was converted into roving on a roving frame which further attenuates the sliver. Twist was inserted to add cohesion to the strand. The roving was then spun on a ring spinning machine in which further drafting took place and twist was inserted to form the final yarn.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Textile Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
  • Artificial Filaments (AREA)
  • Nonwoven Fabrics (AREA)

Abstract

An absorbent, composite fibre comprising a matrix of from 10 % to less than 50 % of water insoluble alginate having dispersed therein at least 40 % of another polysaccharide.

Description

COMPOSITE FIBRES. WOUND DRESSINGS INCORPORATING SUCH
FIBRES AND A METHOD FOR MAKING SAME
The invention relates to composite fibres, particularly absorbent composite fibres for use in wound treatment, wound dressings incorporating such fibres and a method for making same.
Absorbent fibres for use in wound treatment are well known in the art. Examples include cellulose fibres, chemically modified cellulose fibres, pectin fibres, alginate fibres, chitosan fibres, hyaluronic acid fibres or other polysaccharide fibres or fibres derived from gums. In the treatment of wounds it is desirable to use fibres made from pectin or carboxymethyl cellulose but the known processes for making such fibres are complex and expensive and the resulting fibres not always viable. For instance it is known to make carboxymethyl cellulose fibres by chemically converting preformed cellulose fibres. It is also known that both pectin fibres and carboxymethyl cellulose fibres are difficult to spin.
It has been proposed in GB 2062652 A to make cellulose fibres comprising anionically modified polysaccharides by adding the polysaccharide to preformed viscose. Similarly in US 4063558 there is described a method for making fibres of cellulose with alkali metal salts of alginic acid uniformly dispersed therein by adding a solution of sodium alginate to preformed viscose. In WO 96/10106 there are described fibres which preferably comprise from 70 to 95% by weight of an alginate co-spun with from 5 to 30% by weight of at least one water soluble organic polymeric species (other than alginate) .
We have now found that, it is possible to make a composite, absorbent fibre comprising a matrix of water insoluble alginate having another polysaccharide dispersed therein where the fibre comprises less than 50% by weight of the alginate, the fibre mitigating the disadvantages of the prior art fibres.
Accordingly the invention provides an absorbent, composite fibre comprising a matrix of at least 10% and less than 50% by weight of water insoluble alginate having dispersed therein at least 40% of another polysaccharide. Unless otherwise stated all percentages herein are by weight based on the weight of the fibre.
Whilst not wishing to be bound by theory it is believed that the water insoluble alginate effectively provides, as a matrix, a molecular backbone to the fibre that enables the other polysaccharides to be incorporated and results in a fibre that may be spun and otherwise processed. The use of water insoluble alginate for this purpose enables the fibres to be made without the need for complex and expensive processing and without the need to use preformed cellulose as a starting material. Preferred polysaccharides for addition to the alginate backbone are carboxymethyl cellulose and/or pectin. Since it is believed that the fibres of the invention rely on the water insoluble alginate to provide integrity to the fibres it is truly surprising that it is possible to make viable fibres processable into products that comprise a minor proportion of insoluble alginate. One of the advantages of such fibres is that they may comprise a major proportion of polysaccharide other than alginate which generally makes them more absorbent than fibres which have insoluble alginates in a major proportion.
Preferably the fibres comprise, in addition to insoluble alginate, from 40% to 90% of another polysaccharide, more preferably from 60% to 85% and most preferably from 70% to 80% of another polysaccharide which is most preferably carboxymethyl cellulose or pectin or a mixture thereof. Polysaccharides suitable for use in fibres according the invention include carboxymethyl cellulose, carboxyethyl cellulose, other derivatives of cellulose, cellulose, pectin, hyaluronic acid and chitosan. Preferably the insoluble alginate is calcium alginate.
Preferably the fibres comprise from 10% to less than 50% by weight of the fibre of insoluble alginate, more preferably 10% to 49%, more preferably 15% to 40% and most preferably from 20% to 30% by weight of the fibre of water insoluble alginate. Preferably the insoluble alginate is calcium alginate.
A particularly preferred embodiment of the absorbent, composite fibres of the invention comprise a matrix of 20% to 30% of calcium alginate based on the weight of the fibre having dispersed therein from 55% to 60% of carboxymethyl cellulose and 15% to 20% of pectin based on the weight of the fibre.
Accordingly in another aspect the invention provides a method for making a composite, absorbent fibre comprising the following steps: (i) adding sodium alginate and another polysaccharide to water to form a dope,-
(ii) forcing the dope through a spinneret to form fibres,- (iii) treating the resulting fibres with a source of calcium ions to convert the alginate to calcium alginate and cross-link the alginate to the other polysaccharide; (iv) drying the fibres.
The process enables composite fibres to be prepared which comprise large quantities of other polysaccharides and in particular, carboxymethyl cellulose, pectin or both. The fibres so produced are capable of being spun or otherwise mechanically processed. In addition the resulting fibres have a high tensile strength compared to alginate, carboxymethyl cellulose or pectin alone.
As used herein the term fibre means both relatively short, discrete, randomly oriented material (sometimes known as staple fibre) and yarns made therefrom (sometimes known as staple yarn) and relatively long, structured, continuous filament yarn. The fibres may have a staple length of 5mm to 70 mm, more usually 20mm to 50 mm, favourably 25mm to 40 mm.
The fibres prepared according to the above described process may be dried using conventional methods, for example, using acetone or hot air drying.
Alginates are produced by a variety of micro-organisms and marine algae which are the normal commercial source. The alginates being natural materials show considerable variety but are characterised in being block copolymers, the individual monosaccharide units being arranged into groups as blocks of mannuronic (M) and guluronic (G) residues. In addition to the repeating blocks each polymer chain can contain a proportion of alternating M and G monosaccharide units. The alginate may be obtained from any convenient source, for example L. Hyperborea or Ascophyllum Nodosum or those described in EP-A-0721355 to Bristol-Myers Squibb Company which are particularly preferred.
In a further embodiment of the invention the absorbent, composite fibres are employed in the manufacture of wound dressings. Accordingly the invention provides a wound dressing comprising an absorbent, composite fibre comprising a matrix of between at least 10% and less than 50% of water insoluble alginate having dispersed therein at least 40% of another polysaccharide.
The wound dressings may be in the form of swabs, wound pads, wadding ribbons, sponges, nets and bandages and may be used as a primary or secondary dressing especially in the treatment of leg ulcers. The wound dressings according to the invention may benefit from an improved integrity over that of dressings made from alginate, pectin or carboxymethyl cellulose alone.
According to a further aspect of the invention there is provided a wound dressing comprising a mixture of discrete textile fibres and discrete absorbent, composite fibres said absorbent, composite fibres comprising a matrix of at least 10% of water insoluble alginate having dispersed therein at least 40% of another polysaccharide. Such a dressing may have the advantage that it is non-adherent to wound tissue while being absorbent and relatively inexpensive and the added advantage that it may be retained on the wound for longer than conventional cotton gauze. The absorbent, composite fibres according to the invention incorporated in the wound dressing become moist and slippery or gelatinous upon the uptake of wound exudate. This reduces the tendency for the textile fibres to adhere to the wound.
In general textile fibres absorb liquids by capillary action and are not hygroscopic. This means that their absorbencies as measured by the free swell absobancy test are low such as less than l gram of liquid per gram of fibre. Suitable textile fibres can be natural or synthetic depending on the end use of the dressing and method of manufacture. Suitable textile fibres are for instance described in PCT/GB95/00114. For example where the dressing is made from a non-woven mixture of discrete fibres the textile fibre is preferably one that can be fused at relatively low temperatures, for example polypropylene. The entire dressing can be heat fused to give a dressing with sufficient tensile strength that it may be removed intact from the wound even though saturated with exudate. This avoids the need for the painstaking removal from the wound of parts of a dressing that has lost its integrity on exposure to exudate.
Where the dressing is made from a woven mixture of discrete fibres the textile yarn can be polyester, polypropylene or polyamide or any other suitable support yarn. We have surprisingly found that it is possible to knit fibres of the invention in a knitting process where it is preferable for the textile yarn to form the pillar or chain stitches of the knit (the warp) and the composite fibre to form or be included in the the in-laid yarn of the knit. A particularly suitable knit of this type is a Raschel knit as described in Textile Science by Kathryn Hatch, West Publishing Company 1993. If composite fibres are included in both the pillar and the in-laid yarn then the pillar yarn tends to break and shed fibres. If composite fibres are included only in the in-laid yarn then this tendancy is overcome and quite high machine knitting speeds can be achieved and a dressing of better integrity is produced.
According to a further aspect the invention provides a wound dressing as claimed in claims 11 to 14 wherein the dressing is in the form of a warp knitted fabric comprising pillar yarn and in-laid yarn, the pillar yarn being substantially free of composite fibres.
Various optional ingredients can be included in the final composition of the fibres such as preservatives and small amounts of pharmacologically active ingredients. For example an antibiotic or antimicrobial agent such ε metronidazole, silver sulphadiazine, neomycin or penicillin and antiseptic agent such as povidone iodine, iodine and antiinflammatory agent such as hydrocortisone or triamcinolone acteonide or a skin protective agent such as a zinc oxide can be included.
The invention is illustrated by the following examples:
Example 1
Fibres according to the invention in the form of a continuous yarn were prepared as follows:
800ml of a 6% w/w dope was made by adding 28g of carboxymethyl cellulose (ex Hercules) , 12g of alginate (ex Kelco) , and 8g of pectin (ex Aldrich Ltd) to 752g of deionised water. The mixture was stirred with a high speed mixer until the ingredients had dissolved and the dope allowed to stand overnight to degas.
The degassed dope was then poured into a pressure vessel connected to the dope pumping/filtering system of a spinning rig. The pressure vessel was pressurised to 2 to 3 atmospheres with compressed air and the pump, 60μm pore size filter and associated pipe work purged to remove any air bubbles. A 400 jet spinneret, previously ultrasonically cleaned for 20 minutes, was connected to the rig and the rig started. On exit from the spinneret, the dope was fed into a spin bath of 2m length containing 30L of 0.4 mol/dm3 of calcium chloride. The fibres so produced were threaded over three sets of rollers of a first godet and then over the rollers of a second godet. Propan-2-ol was dripped onto the fibres at a rate sufficient to wet the resulting yarn. The yarn was then passed into two baths, the first contained 4L of propan-2-ol and the second contained 2.5L of propan-2-ol. The propan-2-ol was maintained at a concentration to dry the yarn. The yarn was then passed through a set of pinch rollers that serve to apply tension to yarn. The yarn was then wound onto cones. The dope was supplied to the system at 6ml per minute and a speed differential maintained between the first and second godets resulted in a stretch of 60%. The resulting yarn had a denier of 300 to 400.
Example 2
A knitted wound dressing according to the invention was prepared comprising the yarn of example 1 and a crimped polyester yarn. The dressing was knitted on a crochet knitting machine (Model STP7 ex KOHLER) each needle of which creates a chain of interlocked loops (pillar or clain stitches) . These form the warp threads of the dressing. The warp threads are held together by weft threads. 45 warp threads of stiches were knitted from 150 denier crimped polyester yarn. These were held together by 44 threads of the yarn of example 1 (in-laid yarn) to form a dressing.
Example 3
A non-woven wound dressing according to the invention was made by mixing 200g of the aborbent, composite fibres of example 1 cut into 5cm lengths and 200g of polypropylene staple fibre cut to 5cm lengths in a rag roller to randomise the fibre. The mixture of fibres was then carded and cross-lapped into a web of lOOgsm basis weight. The web was then passed through heated callender rollers at 65°C and pressure. The resultant product was slit into discrete dressings 10cm by 10cm square.
Example 4
A staple yarn was made from the composite fibres of the invention in the following way. A mixture of the composite fibre (20kg) and polypropylene (20kg) (all 3 denier) was cut to a staple length of 40mm and converted into a lap of approximately lOOgsm on a conventional short staple scutching line - a Truteschler Opening line. The line comprised a feed table, coarse fibre opener, volumetric feeder, fine opener and lap former.
The lap once formed was fed into a worsted type carding machine - a Thibeau CA6 comprising a weigh pan hopper, fibre opening section and a main carding cylinder. The web of fibres formed was condensed into the form of a sliver with an average weight of 5 grammes per metre length.
The slivers were then attenuated on a conventional short- staple draw frame - a Platts Globe Draw Frame - in which rollers operated at differential surface speeds to attenuate the multiple feed of slivers (6-8) into a uniform single sliver of uniform weight and thickness (approximately 3g per metre length) .
The drawn sliver was converted into roving on a roving frame which further attenuates the sliver. Twist was inserted to add cohesion to the strand. The roving was then spun on a ring spinning machine in which further drafting took place and twist was inserted to form the final yarn.

Claims

1. An absorbent, composite fibre comprising a matrix of from at least 10% to less than 50% by weight of water insoluble alginate having dispersed therein at least 40% by weight of another polysaccharide.
2. An absorbent composite fibre as claimed in claim l wherein the water insoluble alginate is calcium alginate.
3. An absorbent composite fibre as claimed in claim l or claim 2 wherein the other polysaccharide is selected from the group comprising carboxymethyl cellulose, carboxyethyl cellulose, other derivatives of cellulose, cellulose, pectin, hyaluronic acid and chitosan.
4. An absorbent composite fibre as claimed any preceding claim wherein the fibres comprise from 40% to 90% by weight of another polysaccharide, preferably 60% to 85% by weight.
5. An absorbent composite fibre as claimed in any preceding claim wherein the fibres comprise from 70% to 80% by weight of another polysaccharide.
6. An absorbent, composite fibre as claimed in any preceding claim wherein the other polysaccharide is carboxymethylcellulose or pectin or a mixture thereof .
7. An absorbent, composite fibre as claimed in any preceding claim wherein the fibres comprise from 10% to 49% by weight of the fibre of calcium alginate, preferably 30% to 40%.
8. An absorbent, composite fibre as claimed in any preceding claim wherein the fibres comprise from 20% to 30% by weight of the fibre of calcium alginate.
9. A method for making a composite, absorbent fibre comprising the following steps:
(i) adding sodium alginate and another polysaccharide to water to form a dope,-
(ii) forcing the dope through a spinneret to form fibres; (iii) treating the resulting fibres with a source of ions to convert the alginate to water insoluble alginate and cross-link the alginate to the other polysaccharide; (iv) drying the fibres.
10. A method as claimed in claim 8 wherein the source of ions in step (iii) is calcium ions.
11. A wound dressing comprising an absorbent, composite fibre comprising a matrix of from 10% to less than 50% of water insoluble alginate having dispersed therein at least 40% of another polysaccharide.
12. A wound dressing comprising a mixture of discrete textile fibres and discrete absorbent, composite fibres said absorbent, composite fibres comprising a matrix of from 10% to less than 50% of water insoluble alginate having dispersed therein at least 40% of another polysaccharide.
13. A wound dressing as claimed in claim 12 comprising from 50% by weight to 95% by weight of textile fibres and 5% by weight to 50% by weight of absorbent, composite fibres.
14. A wound dressing as claimed in any claim 11 or claim 12 comprising from 75% to 90% by weight of textile fibres and 10% to 25% by weight of absorbent, composite fibres.
15. A wound dressing as claimed in claims 11 to 14 wherein the fibres are in the form of a woven fabric.
16. A wound dressing as claimed in claims 11 to 15 wherein the fibres are in the form of a carded web.
17. Use of a wound dressing as claimed in claims 11 to 16 for the treatment of a wound by placing the dressing in direct contact with the wound.
18. A wound dressing as claimed in claims 12 to 15 wherein the dressing is in the form of a knitted fabric comprising support yarn and in-laid yarn, the support yarn being substantially free of composite fibres.
19. A wound dressing as claimed in claim 18 wherein the fabric is a warp knitted fabric.
EP19970918136 1996-04-12 1997-04-11 Composite fibres, wound dressings incorporating such fibres and a method for making same Expired - Lifetime EP0892863B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9607600.5A GB9607600D0 (en) 1996-04-12 1996-04-12 Composite fibres, wound dressings incorporating such fibres and a method for making same
GB9607600 1996-04-12
GBGB9618658.0A GB9618658D0 (en) 1996-09-06 1996-09-06 Composite fibres,wound dressings incorporating such fibres and a method for making same
GB9618658 1996-09-06
PCT/EP1997/001880 WO1997039170A1 (en) 1996-04-12 1997-04-11 Composite fibres, wound dressings incorporating such fibres and a method for making same

Publications (2)

Publication Number Publication Date
EP0892863A1 true EP0892863A1 (en) 1999-01-27
EP0892863B1 EP0892863B1 (en) 2001-06-20

Family

ID=26309112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19970918136 Expired - Lifetime EP0892863B1 (en) 1996-04-12 1997-04-11 Composite fibres, wound dressings incorporating such fibres and a method for making same

Country Status (11)

Country Link
US (1) US6140257A (en)
EP (1) EP0892863B1 (en)
JP (1) JP2000508385A (en)
AT (1) ATE202388T1 (en)
AU (1) AU711723B2 (en)
CA (1) CA2250473C (en)
DE (1) DE69705303T2 (en)
DK (1) DK0892863T3 (en)
ES (1) ES2157568T3 (en)
NZ (1) NZ332112A (en)
WO (1) WO1997039170A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058311A1 (en) 2009-11-10 2011-05-19 Convatec Technologies Inc. A component for a wound dressing
WO2023175334A1 (en) 2022-03-16 2023-09-21 Convatec Limited Wound dressing
WO2023175332A1 (en) 2022-03-16 2023-09-21 Convatec Limited Wound dressing
WO2023175331A1 (en) 2022-03-16 2023-09-21 Convatec Limited Wound dressing

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100379462C (en) 1999-11-09 2008-04-09 电气化学工业株式会社 Use of soluble cellulose derivative having been made hardly soluble in water and process for producing the same
GB0011053D0 (en) 2000-05-09 2000-06-28 Hudson John O Medical device and use thereof
GB0026863D0 (en) * 2000-11-03 2000-12-20 Ssl Int Plc Polysaccharide fibres
GB0107655D0 (en) * 2001-03-27 2001-05-16 Bristol Myers Squibb Co Wound dressing
US6759073B2 (en) 2001-07-02 2004-07-06 The Procter & Gamble Co. Compositions and methods for stabilization and enhanced viscosity
US6838109B2 (en) 2001-07-02 2005-01-04 The Proctor & Gamble Company Fatty acid compositions having superior stability and flavor properties
DE60223930T2 (en) * 2001-09-12 2008-11-06 ConvaTec Ltd., Deeside ANTIBACTERIAL WOUND ASSOCIATION
JP4969768B2 (en) 2002-04-04 2012-07-04 ザ ユニバーシティ オブ アクロン Nonwoven fiber assembly
US8367570B2 (en) 2002-04-04 2013-02-05 The University Of Akron Mechanically strong absorbent non-woven fibrous mats
US6855750B2 (en) * 2002-09-17 2005-02-15 Mccormick Edmund J. Method and apparatus for creating molds
US20050152955A1 (en) * 2003-12-16 2005-07-14 Akhave Jay R. Electrostatically self-assembled antimicrobial coating for medical applications
PL1718257T3 (en) 2004-02-13 2011-01-31 Convatec Technologies Inc Multi layered wound dressing
WO2006101453A1 (en) * 2005-03-22 2006-09-28 Agency For Science, Technology And Research Scaffold and method of forming scaffold by entangling fibres
WO2007027849A2 (en) * 2005-08-31 2007-03-08 Board Of Regents, The University Of Texas System Multiribbon nanocellulose as a matrix for wound healing
GB0603122D0 (en) * 2006-02-16 2006-03-29 Univ Bolton Higher Education C Improvements in and relating to composites
WO2008010199A2 (en) * 2006-07-18 2008-01-24 Nanopeutics S.R.O. A nanofibre product
DE102006047041A1 (en) 2006-10-02 2008-04-10 Birgit Riesinger Areal absorbent body
GB0710846D0 (en) * 2007-06-06 2007-07-18 Bristol Myers Squibb Co A wound dressing
WO2010028025A1 (en) 2008-09-02 2010-03-11 Gurtner Geoffrey C Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
CN101665995B (en) * 2008-09-05 2011-09-14 中国科学院大连化学物理研究所 Sodium alga acid/chitosan composite fluid spinning method
GB2463523B (en) 2008-09-17 2013-05-01 Medtrade Products Ltd Wound care device
AT508688B8 (en) * 2009-08-28 2011-10-15 Chemiefaser Lenzing Ag CARBOXYETHYL CELLULOSE FIBERS, THEIR USE IN WOUND ALLOYS AND HYGIENE ITEMS AND METHOD FOR THE PRODUCTION THEREOF
GB201012333D0 (en) * 2010-07-22 2010-09-08 Convatec Technologies Inc Fibres, a process for producing such fibres and a wound dressing incorporating them
US20130303480A1 (en) * 2010-10-20 2013-11-14 Tautona Group Lp Soft tissue augmentation threads and methods of use thereof
US20130085434A1 (en) * 2011-09-30 2013-04-04 Tyco Healthcare Group Lp Wound Dressing And Related Methods Therefor
CN104069536B (en) * 2014-07-11 2016-01-20 江苏开源康达医疗器械有限公司 A kind of preparation method preparing sodium alginate-chitosan nanoscale medical dressing
US9610379B2 (en) 2015-01-23 2017-04-04 Fpinnovations Absorbent fibres produced from low-substituted carboxymethyl cellulose and the process thereof
US20180326113A1 (en) * 2015-11-18 2018-11-15 Advanced Medical Solutions Limited Fibres
EP3402462B1 (en) 2016-01-12 2020-03-11 Council of Scientific & Industrial Research A nanobiocomposite formulation for wound healing and a process for the preparation thereof
CN107029272B (en) * 2017-04-10 2020-04-10 河南汇博医疗股份有限公司 Alginate medical dressing and preparation method thereof
CN110241481A (en) * 2019-05-28 2019-09-17 福建美可纸业有限公司 A kind of superabsorbent water composite fibre and preparation method thereof
DE102019007165A1 (en) * 2019-10-15 2021-04-15 Smartfiber Ag Process for the production of a cellulosic functional fiber with high ion exchange capacity and cellulosic functional fiber
GB2588439A (en) * 2019-10-24 2021-04-28 Io Cyte Ltd Swellable antimicrobial fibre

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61289886A (en) * 1985-06-19 1986-12-19 Agency Of Ind Science & Technol Production of fiber of alginic acid containing active protein and paper made of said fiber
JPS6342917A (en) * 1986-08-07 1988-02-24 Agency Of Ind Science & Technol Production of fiber with adsorption activity
GB9400994D0 (en) * 1994-01-20 1994-03-16 Bristol Myers Squibb Co Wound dressing
DE69532242T2 (en) * 1994-09-29 2004-09-16 Advanced Medical Solutions Ltd., Winsford wound dressing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9739170A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058311A1 (en) 2009-11-10 2011-05-19 Convatec Technologies Inc. A component for a wound dressing
US10543133B2 (en) 2009-11-10 2020-01-28 Convatec Technologies Inc. Component for a wound dressing
WO2023175334A1 (en) 2022-03-16 2023-09-21 Convatec Limited Wound dressing
WO2023175332A1 (en) 2022-03-16 2023-09-21 Convatec Limited Wound dressing
WO2023175331A1 (en) 2022-03-16 2023-09-21 Convatec Limited Wound dressing

Also Published As

Publication number Publication date
DE69705303T2 (en) 2002-04-25
DK0892863T3 (en) 2001-09-24
ATE202388T1 (en) 2001-07-15
CA2250473C (en) 2004-06-08
JP2000508385A (en) 2000-07-04
CA2250473A1 (en) 1997-10-23
DE69705303D1 (en) 2001-07-26
WO1997039170A1 (en) 1997-10-23
AU2637897A (en) 1997-11-07
AU711723B2 (en) 1999-10-21
EP0892863B1 (en) 2001-06-20
US6140257A (en) 2000-10-31
NZ332112A (en) 2000-06-23
ES2157568T3 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
EP0892863B1 (en) Composite fibres, wound dressings incorporating such fibres and a method for making same
AU719928B2 (en) Knitted wound dressings and method for making same
CA2179415C (en) Non-adherent wound dressing of gel-forming and textile fibres
EP2785387B1 (en) Wound dressing for use in vacuum therapy
US6458460B1 (en) Wound dressing
CN114045588B (en) Multi-layer composite core-spun yarn and fabric based on hydrophilic modified chitosan fiber
CN114045587B (en) Composite yarn hemostatic material based on hydrophilic modified chitosan
WO1999064080A1 (en) Yarns and wound dressings containing the same
MXPA98008311A (en) Composite fibers, wood bandage that includes such fibers and a method to manufacture lasmis
CN1068158A (en) The method for making of absorbable hemostatic dressing
NZ332977A (en) Knitted wound dressing comprising gel-forming fibres
Uzun et al. Development of novel yarns containing carboxymethyl cellulose and alginate fibers for wound dressing applications
AU716252C (en) Wound dressing
NZ626694B2 (en) Wound dressing for use in vacuum therapy
JPS6297557A (en) Wound surface protective material

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

17Q First examination report despatched

Effective date: 20001123

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010620

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20010620

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010620

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010620

REF Corresponds to:

Ref document number: 202388

Country of ref document: AT

Date of ref document: 20010715

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69705303

Country of ref document: DE

Date of ref document: 20010726

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2157568

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20010921

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

BECA Be: change of holder's address

Owner name: CONVATEC TECHNOLOGIES INC.6100 NEIL ROAD, SUITE 50

Effective date: 20090302

BECH Be: change of holder

Owner name: CONVATEC TECHNOLOGIES INC.

Effective date: 20090302

REG Reference to a national code

Ref country code: NL

Ref legal event code: SD

Effective date: 20100303

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20100329

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20100506

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110411

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20160311

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20160314

Year of fee payment: 20

Ref country code: FR

Payment date: 20160309

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20160411

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20160405

Year of fee payment: 20

Ref country code: GB

Payment date: 20160406

Year of fee payment: 20

Ref country code: IE

Payment date: 20160411

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20160330

Year of fee payment: 20

Ref country code: DK

Payment date: 20160412

Year of fee payment: 20

Ref country code: SE

Payment date: 20160412

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69705303

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20170411

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20170410

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20170410

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 202388

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170411

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170410

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20170412